Clinical Trial Update: Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating gemtuzumab ozogamicin in combination with A-HAM in refractory acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: University of Ulm | Conditions: Leukemia, Myeloid, Acute | Phase 2 | Status: COMPLETED